The use of dabrafenib incombination with trametinib has also been emphasized in other BRAF V600E-mutatedcancers, such as stage III melanomas, where this combined therapy was shown tosignificantly improve the OS rate and disease progression in comparison withpatients receiving the standard of care (39). The gene discussed is BRAF; the disease is melanoma.